Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference
June 06, 2018 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, June 06, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio
May 31, 2018 08:45 ET
|
Abeona Therapeutics Inc.
-- The Elisa Linton Center for Rare Disease Therapies to support development of advanced gene and cell therapies for treatment of serious rare diseases -- Ribbon-cutting ceremony of gene and cell...
Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting
May 17, 2018 09:20 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 17, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
May 14, 2018 08:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 14, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
May 11, 2018 08:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 11, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
March 16, 2018 17:10 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and...
Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
January 29, 2018 08:45 ET
|
Abeona Therapeutics Inc.
First gene therapy RMAT designation for Epidermolysis BullosaEnables accelerated approval path and real world data usage NEW YORK and CLEVELAND, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Abeona...
Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
November 15, 2017 08:25 ET
|
Abeona Therapeutics Inc.
Investor Conference Call to be held Monday, November 20th at 10:00 am ETGlobal enrollment continues in ABO-102 trial for MPS IIIAScreening initiated in ABO-101 Phase 1/2 trial for MPS IIIBPivotal...
Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio
October 04, 2017 08:45 ET
|
Abeona Therapeutics Inc
-- Facility to support development of advanced gene and cell therapies for treatment of life-threatening rare diseases -- Leaders from local government, life sciences and medical technology to...
Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa
August 29, 2017 09:05 ET
|
Abeona Therapeutics Inc
FDA recently guided Company to accelerate Phase 3 trial for EB-101 autologous cell therapyBreakthrough Therapy designation enables priority review and expedites approval processEB-101 has demonstrated...